Fulcrum Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • February 27th, 2024 • Fulcrum Therapeutics, Inc. • Pharmaceutical preparations • New York
Fulcrum Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and Stifel, Nicolaus & Company, Incorporated (“Stifel”; each individually an “Agent” and together, the “Agents”), as follows:
